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Introduction
The most common form of crescentic glomeru-
lonephritis and the most common type of necrotizing
systemic vasculitis in adults are associated with circu-
lating antineutrophil cytoplasmic autoantibodies
(ANCAs) (1, 2). ANCAs are specific for antigens in the
primary granules of neutrophils and the peroxidase-
positive lysosomes of monocytes. The two major anti-
gen specificities are for myeloperoxidase (MPO-ANCA)
(3) and proteinase 3 (PR3-ANCA) (4).
Numerous in vitro observations provide strong evi-
dence that both MPO-ANCA and PR3-ANCA are
directly involved in causing the glomerular and vascu-
lar inflammation of ANCA-associated glomeru-
lonephritis and vasculitis (5, 6). For example, ANCA
IgG stimulates cytokine-primed neutrophils and
monocytes to undergo respiratory burst, release toxic
and lytic granule constituents, adhere to endothelial
cells, and kill endothelial cells (5, 6).
Until now, however, in vivo experimental animal obser-
vations have not offered definitive evidence for a patho-
genic role for ANCAs (7). The experiments described in
this article provide compelling evidence that ANCAs are
directly pathogenic. These experiments document the
induction of glomerulonephritis and vasculitis by the
adoptive transfer of mouse anti-MPO splenocytes into
immune-deficient mice or the passive infusion of mouse
anti-MPO IgG into both immune-deficient and im-
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Antineutrophil cytoplasmic autoantibodies (ANCAs) are identified in the circulation of approxi-
mately 80% of patients with pauci-immune necrotizing and crescentic glomerulonephritis and sys-
temic small vessel vasculitis, such as microscopic polyangiitis and Wegener granulomatosis. The most
common antigen target for ANCAs is myeloperoxidase (MPO), which is found in neutrophils and
monocytes. We report definitive experimental animal evidence that ANCAs are pathogenic. MPO
knockout (Mpo–/–) mice were immunized with mouse MPO. Splenocytes from these mice or from con-
trol mice were injected intravenously into recombinase-activating gene-2–deficient (Rag2–/–) mice,
which lack functioning B lymphocytes and T lymphocytes. All mice that received splenocytes devel-
oped mild to moderate glomerular immune deposits, but only mice that received 1 × 108 or 5 × 107
anti-MPO splenocytes developed severe necrotizing and crescentic glomerulonephritis, granuloma-
tous inflammation, and systemic necrotizing vasculitis, including necrotizing arteritis and hemor-
rhagic pulmonary capillaritis. To test the pathogenic potential of antibodies alone, purified anti-
MPO IgG or control IgG was injected intravenously into Rag2–/– mice and wild-type mice. Mice that
received anti-MPO IgG but not mice that received control IgG developed focal necrotizing and cres-
centic glomerulonephritis with a paucity of glomerular Ig deposition. Thus, anti-MPO IgG alone was
able to cause pauci-immune glomerular necrosis and crescent formation in the absence of function-
al T or B lymphocytes in Rag2–/– mice and in the presence of an intact immune system in wild-type
C57BL/6J mice. This animal model offers strong support for a direct pathogenic role for ANCA IgG
in human glomerulonephritis and vasculitis.
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mune-competent mice. The resulting necrotizing and
crescentic glomerulonephritis, pulmonary hemorrhagic
capillaritis, and systemic necrotizing arteritis have
remarkable pathologic similarity to human ANCA-asso-
ciated glomerulonephritis and vasculitis.
Methods
Purification of mouse MPO. Mouse MPO was purified
from WEHI-3 cells (a murine myeloid cell line pur-
chased from American Type Culture Collection, Man-
assas, Virginia, USA) using a modification of the
method of Hope et al. (8). Briefly, WEHI-3 cells were
grown in McCOY5A medium with 10% FCS. Once the
cells reached a density of 1.5 × 106 cells per milliliter,
they were harvested by centrifugation and resuspend-
ed in buffer A (6.7 mM sodium phosphate, pH 6.0; 
1 mM MgCl2; 3 mM NaCl; 0.5 mM PMSF) at a ratio of
10 ml of buffer to 1 ml of cell pellet. The cells were lysed
by Dounce homogenization on ice and then cen-
trifuged at 20,000 g for 30 minutes. The pellets were
resuspended in buffer A. Cetyltrimethylammonium
bromide was added to a final concentration of 1%, and
the mixture was stirred vigorously for 2 hours at 4°C.
The insoluble material was removed by centrifugation
at 20,000 g for 20 minutes at 4°C. The solubilized
material was dialyzed against buffer B (100 mM sodi-
um acetate, pH 6.3; 100 mM NaCl) for 5 hours at 4°C.
CaCl2, MgCl2, and MnCl2 were then added to a final
concentration of 1 mM each. The material was mixed
end-over-end with 5 ml of concanavalin A-Sepharose
(Amersham Pharmacia Biotech, Piscataway, New Jersey,
USA) overnight at 4°C. The resin was poured into a
Bio-Rad Econo-Column (Bio-Rad Laboratories, Her-
cules, California, USA). The MPO was eluted from the
concanavalin A-Sepharose with 3-ml pulses of 750 mM
methyl α-D-mannopyranoside in buffer B plus 1 mM
CaCl2, MgCl2, and MnCl2. The MPO-containing frac-
tions were determined both by the green color and by
A430 values and were dialyzed against buffer C (25 mM
sodium acetate, pH 8.5; 100 mM NaCl) overnight at
4°C. The sample was loaded onto a cation exchange
column (HiTrap SP Sepharose HP [Amersham Phar-
macia Biotech]; 5 ml) and eluted with 1 M NaCl (pH
8.5). The eluate was loaded onto Superose 12 column
(Amersham Pharmacia Biotech) (60 × 1.5 cm) and elut-
ed in buffer C. The isolated MPO was dialyzed against
water and concentrated with Centriprep (Millipore
Corp., Bedford, Massachusetts, USA) at 2,000 g. The
purity of the isolated MPO was confirmed by SDS-
PAGE and Western blot.
Mice. Mice lacking MPO (Mpo–/– mice) were the sixth-
generation progeny of a backcross into C57BL/6J mice
(B6 mice) originally generated by Aratani et al. (9). Mice
were genotyped using PCR-amplified DNA isolated
from tail clippings. Breeding pairs of B6 recombinase-
activating gene-2–deficient (Rag2–/–) mice were pur-
chased from Taconic (Germantown, New York, USA)
and maintained by the University of North Carolina
Division of Laboratory Animal Medicine in “clean
rooms” in autoclaved cages with microisolator tops.
Rag2–/– mice lack the ability to initiate V(D)J rearrange-
ment and thus do not produce T or B lymphocytes with
antigen receptors (10). Mpo–/– mice, 8–10 weeks old,
were used for immunization and as donors of spleno-
cytes and anti-MPO antibodies. Rag2–/– mice (10–12
weeks old), Mpo–/– mice (13 weeks old), and wild-type
(WT) B6 mice (9–10 weeks old) were used as recipients
for adoptive transfer experiments. Table 1 summarizes
the characteristics of the experimental groups. The Uni-
versity of North Carolina Institutional Animal Care and
Use Committee approved all animal experiments.
Immunization and detection of anti-MPO. Mpo–/– mice
were primed by intraperitoneal injection of 10 µg of
purified MPO or BSA in complete Freund’s adjuvant
on day 0. They were boosted intraperitoneally with the
10 µg MPO in incomplete Freund’s adjuvant on day 21
and day 36, and boosted by intravenous injection of 10
µg MPO without adjuvant 4 days before splenocytes
were harvested. Development of antibodies was mon-
itored by anti-MPO ELISA. Circulating anti-MPO was
confirmed in selected animals by indirect immuno-
fluorescence microscopy assay (IFA). For anti-MPO
ELISA, microtiter plates were coated with 0.5 µg per
well murine MPO, incubated with 100-fold dilutions
of mouse sera, developed with alkaline phos-
phatase–conjugated goat antibodies specific for
mouse IgG, and analyzed spectrophotometrically at
OD 405 nm. Results were expressed as percentage of a
positive control serum pool. For IFA, mouse neu-
trophils were harvested from the peritoneum of B6 or
Mpo–/– mice 4 hours after intraperitoneal injection of
3% sterilized Proteose peptone (Difco Laboratories,
Detroit, Michigan, USA). Isolated cells were washed in
PBS with 0.05 mM EDTA and adjusted to 1 × 106 cells
per milliliter. More than 50% of isolated cells were
polymorphonuclear neutrophils, and the remainder
were mononuclear leukocytes. Cells were cytocen-
trifuged onto glass slides, air-dried, and fixed with
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Table 1
Experimental animal groups
Mouse strain n Male/Female Received
Rag2–/– 12 5/7 1 × 108 anti-MPO cells
Rag2–/– 4 2/2 5 × 107 anti-MPO cells
Rag2–/– 4 2/2 1 × 107 anti-MPO cells
Rag2–/– 6 2/4 1 × 108 anti-BSA cells
Rag2–/– 4 2/2 5 × 107 anti-BSA cells
Rag2–/– 4 2/2 1 × 107 anti-BSA cells
Rag2–/– 6 4/2 1 × 108 nonimmunized cells
Rag2–/– 3 2/1 5 × 107 nonimmunized cells
Rag2–/– 3 2/1 1 × 107 nonimmunized cells
Mpo–/– 4 2/2 6.5 × 107 anti-MPO cells
Rag2–/– 5 0/5 50 µg/g anti-MPO IgG
Rag2–/– 3 0/3 50 µg/g anti-BSA IgG
Rag2–/– 4 4/0 None
WT B6 6 0/6 50 µg/g anti-MPO IgG
WT B6 3 0/3 50 µg/g anti-BSA IgG
100% ethanol for 5 minutes. Serum diluted 1:20 was
incubated with the substrate neutrophils for 45 min-
utes at room temperature, then washed with PBS.
Bound antibody was detected with a 1:50 dilution of
FITC-conjugated rabbit anti-mouse IgG (DAKO
Corp., Carpinteria, California, USA). Neutrophils from
Mpo–/– mice were used as negative controls.
Adoptive transfer of splenocytes and Ig. We isolated
splenocytes from immunized and control Mpo–/– mice
by disrupting the spleens into cold RPMI 1640 medi-
um and then washing twice with RPMI 1640. Red
blood cells were removed with lysis buffer (Sigma-
Aldrich, St. Louis, Missouri, USA) followed by washing
with RPMI 1640 and final suspension in sterile PBS.
Suspensions of 1 × 107, 5 × 107, or 1 × 108 splenocytes
in 500 µl PBS were administered via the tail vein to
Rag2–/– mice (n = 46) (Table 1). A group of Mpo–/– mice
(n = 4) received 6.5 × 107 anti-MPO splenocytes. No dif-
ferences were observed between males and females in
any of the experimental parameters measured.
γ-Globulins were isolated from serum of Mpo–/– mice
immunized with MPO or BSA by 50% ammonium sul-
fate precipitation. IgG was isolated from the γ-globulin
using HiTrap protein G HP column affinity chro-
matography (Amersham Pharmacia Biotech). The puri-
fied IgG was dialyzed against PBS. Sterile-filtered IgG
in PBS was injected via the tail vein at a concentration
of 50 µg/g mouse weight. Five Rag2–/– mice received
anti-MPO IgG and three received anti-BSA IgG; and six
WT B6 mice received anti-MPO IgG and three received
anti-BSA IgG (Table 1). Induction of circulating anti-
MPO (MPO-ANCA) by adoptive transfer of lympho-
cytes and by passive transfer of IgG was monitored by
anti-MPO ELISA and by ANCA IFA.
Laboratory and pathologic evaluation of disease induction.
Mice were placed in metabolic cages for 12 hours to
collect urine for analysis. Urine was tested by dipstick
for hematuria, proteinuria, and pyuria (Roche Diag-
nostics Corp., Indianapolis, Indiana, USA). Serum cre-
atinine and blood urea nitrogen (BUN) were meas-
ured using a Johnson & Johnson Clinical Diagnostics
VITROS 250. Mice were euthanized with methoxyflu-
rane. At the time of postmortem examination, sam-
ples of kidney, lung, liver, spleen, and lymph node
(axillary or inguinal) were fixed in 10% formalin and
processed for light microscopy. Three B6 mice that
received anti-MPO IgG had focal ear ulcers that were
sampled for histologic examination. All specimens
were stained with hematoxylin and eosin (H&E), and
periodic acid Schiff stains, and selected specimens
were stained with Masson trichrome and phospho-
tungstic acid hematoxylin stains. A sample of each
kidney was snap-frozen and processed for direct
immunofluorescence microscopy using FITC-labeled
antibodies specific for mouse IgG, IgA, IgM, C3,
MPO, and fibrin. Selected kidney specimens were
fixed in glutaraldehyde and processed for electron
microscopy. Pathologic evaluation was carried out
without knowledge of the experimental conditions.
Results
Development of circulating MPO-ANCA after transfer of anti-
MPO splenocytes. Rag2–/– mice that received anti-MPO
splenocytes developed circulating anti-MPO (MPO-
ANCA) within 3 days (Figure 1). The titer continued to
rise until sacrifice at 13 days. There was a dose response
to anti-MPO splenocytes, with a dose of 1 × 107 spleno-
cytes producing a substantially lower induction of cir-
culating anti-MPO antibodies compared with a dose of
1 × 108 or 5 × 107 splenocytes. Mice that received
splenocytes from control mice that had been immu-
nized with anti-BSA or had not been immunized did
not develop anti-MPO antibodies. Nonimmunized
Mpo–/– mice that received 6.5 × 107 anti-MPO spleno-
cytes had mean anti-MPO ELISA titers of 12.1, 75.6,
90.6, and 98.9 at days 0, 3, 8, and 13, respectively. The
presence of anti-MPO antibodies in Rag2–/– mice was
confirmed by indirect IFA using normal mouse neu-
trophils as positive substrate and Mpo–/– mouse neu-
trophils as negative control.
Development of necrotizing and crescentic glomerulonephri-
tis, granulomatous inflammation, and vasculitis after transfer
of anti-MPO splenocytes. Rag2–/– mice that received 1 × 108
or 5 × 107 anti-MPO splenocytes developed severe renal
failure that resulted in marked elevation of BUN and
serum creatinine (Figure 2). In contrast, Rag2–/– mice
that received 1 × 107 anti-MPO splenocytes, or any dose
of anti-BSA splenocytes or control splenocytes, devel-
oped minimal if any renal insufficiency. Urinalysis
revealed that all Rag2–/– mice that received splenocytes
developed urine abnormalities (Figure 3). However,
Mpo–/– mice that received 6.5 × 107 anti-MPO spleno-
cytes developed no urine abnormalities (data not
shown). The urine abnormalities that developed in
Rag2–/– mice that received splenocytes were dose-
dependent in all groups. No effects of sex on these or
any other measures of disease induction were observed.
Gross examination revealed hemorrhagic dots on the
surface of the kidneys in mice that received 1 × 108 or 
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Figure 1
Anti-MPO antibody ELISA titers in Rag2–/– mice that received 1 × 108
anti-MPO splenocytes (closed diamonds), 5 × 107 anti-MPO
splenocytes (filled squares), 1 × 107 anti-MPO splenocytes (filled
triangles), 1 × 108 anti-BSA splenocytes (open triangles), or 1 × 108
splenocytes from nonimmunized mice (open circles). Mice that
received 5 × 107 or 1 × 107 anti-BSA splenocytes had no values
above 15 (data not shown).
5 × 107 anti-MPO splenocytes but not in mice that
received other doses of splenocytes. All 16 Rag2–/– mice
that received 1 × 108 or 5 × 107 anti-MPO splenocytes
developed severe necrotizing and crescentic glomeru-
lonephritis (Figure 4; Figure 5, c and d). Crescents
involved an average of 83.8% of glomeruli in mice that
received 1 × 108 anti-MPO splenocytes (range 35–99%)
and 85.0% in mice that received 5 × 107 anti-MPO
splenocytes (range 48–99%) (Figure 4). None of the 30
Rag2–/– mice that received anti-BSA or control spleno-
cytes or 1 × 107 anti-MPO splenocytes developed
glomerular crescents (Figure 4). All Rag2–/– mice that
received 1 × 108 or 5 × 107 anti-MPO splenocytes devel-
oped segmental or global glomerular necrosis, often in
association with crescent formation. Necrosis involved
an average of 63.3% of glomeruli in mice that received
1 × 108 anti-MPO splenocytes (range 33–87%) and
82.5% in mice that received 5 × 107 anti-MPO spleno-
cytes (range 42–97%). Necrosis was rare in mice that
received anti-BSA or control splenocytes or 1 × 107 anti-
MPO splenocytes (Figure 4).
Most mice that received 1 × 108 or 5 × 107 anti-MPO,
anti-BSA, or normal control splenocytes developed
mild to moderate glomerular endocapillary hypercel-
lularity that was similar irrespective of the type of
splenocytes received (Figures 4 and 5b). Mice that
received 1 × 107 splenocytes had minimal or no histo-
logic renal abnormalities (Figure 5a).
Of the 16 Rag2–/– mice that received 1 × 108 or 5 × 107
anti-MPO splenocytes, one was found to have necrotiz-
ing arteritis in spleen and lymph nodes, one necrotizing
arteritis in the lungs, five hemorrhagic pulmonary cap-
illaritis, and one necrotizing granulomatous inflam-
mation in the spleen (Figure 6). The light microscopic
appearance of these lesions was identical to that of
human ANCA-associated vasculitis, such as microscop-
ic polyangiitis and Wegener granulomatosis. None of
the 30 Rag2–/– mice that received 1 × 107 anti-MPO
splenocytes, or any dose of anti-BSA splenocytes or con-
trol splenocytes, was found to have vasculitis or granu-
lomatous inflammation.
Immunofluorescence microscopy demonstrated that
all Rag2–/– mice that received anti-MPO, anti-BSA, or
normal control splenocytes developed similar mild to
moderate granular glomerular localization of mouse
Ig’s (Figures 4 and 5f), C3, and MPO. In general, the rel-
ative intensity of staining was C3>IgG>IgM>IgA>MPO.
The staining for MPO colocalized with the immune
deposits and was accentuated at sites of necrosis.
Glomerular staining was more intense in mice that
received 1 × 108 or 5 × 107 splenocytes than in those
that received 1 × 107 splenocytes. Glomerular staining
for MPO was no different in mice that received anti-
MPO splenocytes compared with those that received
anti-BSA or control splenocytes. Only mice that
received 1 × 108 or 5 × 107 anti-MPO splenocytes devel-
oped marked focally variable glomerular staining for
fibrin that corresponded to foci of glomerular necrosis
and crescent formation (Figure 5e). No localization of
Ig’s or complement was identified in renal arteries.
Electron microscopy performed on kidney tissue from
four mice that received 1 × 108 or 1 × 107 anti-MPO
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Figure 2
Mean BUN and serum creatinine in Rag2–/– mice 13 days
after they received 1 × 108, 5 × 107, or 1 × 107 anti-MPO
splenocytes, anti-BSA splenocytes, or nonimmunized con-
trol splenocytes. The normal mouse assay reference range
was 18–29 mg/dl for BUN and 0.2–0.8 mg/dl for serum
creatinine. Samples taken before injection of splenocytes
were within the reference ranges (data not shown).
Figure 3
Urinalysis results in Rag2–/– mice 13 days
after they received 1 × 108, 5 × 107, or 
1 × 107 anti-MPO splenocytes, anti-BSA
splenocytes, or nonimmunized control
splenocytes. Samples taken before injec-
tion of splenocytes showed mean pro-
teinuria 1.0+, hematuria 0.2+, and
leukocyturia 0.0+ (data not shown).
splenocytes and two mice that received 1 × 108 anti-BSA
splenocytes demonstrated mesangial immune com-
plex–type electron-dense deposits in all mice and a few
subendothelial deposits in one mouse in each group.
Areas of segmental necrosis in the mice that received
anti-MPO splenocytes had breaks in glomerular base-
ment membranes, fibrin tactoids in capillary lumens
and Bowman’s space, and cellular crescent formation.
Development of circulating MPO-ANCA after passive trans-
fer of anti-MPO antibodies. A single intravenous dose of
anti-MPO IgG resulted in an immediate high level of
circulating anti-MPO antibodies that subsequently
declined. The mean anti-MPO ELISA titer in Rag2–/–
mice was 15.6 prior to injection of anti-MPO IgG, 136.4
one hour after injection, 102.8 after 3 days, and 76.8
after 6 days. Passive transfer of anti-BSA IgG resulted
in no increase in anti-MPO reactivity in serum, with
mean anti-MPO titers of 15.2, 15.5, 15.3, and 15.2 at 0
hours, 1 hour, 3 days, and 6 days, respectively. The
mean anti-MPO titer in WT B6 mice that received anti-
MPO IgG was 109.5 one hour after injection, 100.7
after 3 days, and 98.7 after 6 days. The mean anti-MPO
titer in WT B6 mice that received anti-BSA IgG was
16.5 one hour after injection, 15.7 after 3 days, and 15.7
after 6 days. The presence of anti-MPO antibodies was
confirmed by indirect immunofluorescence assay on
normal mouse neutrophils.
Development of glomerulonephritis after passive transfer of
anti-MPO antibodies. By day 3, mice that received anti-
MPO IgG already had developed hematuria, protein-
uria, and leukocyturia, which persisted until sacrifice
at day 6 (Table 2). Mice that received anti-BSA IgG did
not develop hematuria, leukocyturia, or proteinuria
above background. Rag2–/– mice that received anti-
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Figure 4
Pathologic findings in Rag2–/– mice 13 days after
they received 1 × 108, 5 × 107, or 1 × 107 anti-
MPO splenocytes, anti-BSA splenocytes, or non-
immunized control splenocytes. The extent of
glomerular crescent formation is expressed as the
mean percent of glomeruli with crescents in each
animal. The extent of glomerular necrosis is
expressed as the mean percent of glomeruli with
necrosis in each animal. The extent of glomeru-
lar endocapillary hypercellularity is expressed as
the mean on a scale of 0 (none) to 4+ (severe).
The extent of glomerular immunostaining for IgG
is expressed as the mean on a scale of 0 (none)
to 4+ (very intense). Normal Rag2–/– mice had no
crescents, necrosis, endocapillary hypercellulari-
ty, or glomerular Ig staining (data not shown).
Figure 5
Glomerular lesions in Rag2–/– mice 13 days
after they received splenocytes. (a) No light
microscopic abnormality in a glomerulus
from a mouse that received 1 × 107 anti-
MPO splenocytes. (b) Moderate (2+) endo-
capillary hypercellularity in a mouse that
received 1 × 108 anti-BSA splenocytes. (c)
Segmental fibrinoid necrosis (arrow) in a
mouse that received 1 × 108 anti-MPO
splenocytes. (d) Cellular crescent (arrow) in
a mouse that received 1 × 108 anti-MPO
splenocytes. (e) Immunofluorescence stain-
ing for fibrin in a crescent in a mouse that
received 1 × 108 anti-MPO splenocytes. (f)
Predominantly mesangial moderate (2+)
immunofluorescence staining for IgG in a
mouse that received 1 × 108 anti-BSA spleno-
cytes. Periodic acid Schiff stain for light
microscopy is shown.
MPO IgG, which had the most severe renal lesions
pathologically, were the only group to have slightly ele-
vated BUN (Table 2). Serum creatinine did not differ
between mice that received anti-MPO IgG (0.3 mg/dl)
and those that received anti-BSA IgG (0.3 mg/dl).
All five Rag2–/– mice sacrificed 6 days after receiving
anti-MPO IgG had focal necrotizing glomerulonephri-
tis (mean 13.2% of glomeruli with necrosis) and crescents
(mean 10.8% of glomeruli with crescents), whereas mice
that received anti-BSA IgG had no histologic lesions
(Table 2; Figure 7). Likewise, all six WT B6 mice sacri-
ficed 6 days after receiving anti-MPO IgG had focal
necrotizing glomerulonephritis (mean 4.7% of glomeruli
with necrosis) and crescents (mean 3.3% of glomeruli
with crescents), whereas WT B6 mice that received anti-
BSA IgG had no histologic lesions (Table 2; Figure 8).
Electron microscopy revealed no immune complex–type
electron-dense deposits in the glomeruli of the five
Rag2–/– mice that received anti-MPO IgG. Immunofluo-
rescence microscopy demonstrated little or no glomeru-
lar staining for Ig’s, C3, or MPO in Rag2–/– and WT B6
mice that received anti-MPO IgG. There was trace
mesangial staining for Ig’s that was no different between
mice that received anti-MPO or anti-BSA IgG. There was
slightly increased focal segmental staining predomi-
nantly for IgG and C3 at sites of necrotizing injury (Fig-
ure 7f). There was trace staining at these sites for MPO.
Mice that received anti-BSA IgG lacked the focal seg-
mental glomerular staining for IgG, C3, and MPO. Mice
that received anti-MPO IgG had intense focal segmental
glomerular staining for fibrin that corresponded to foci
of segmental necrosis and crescent formation (Figures
7e and 8d). There was no staining for fibrin in glomeruli
of mice that received anti-BSA IgG. The paucity of stain-
ing for Ig’s and complement in the glomeruli of mice
with glomerulonephritis induced by anti-MPO IgG was
identical to the pattern of staining seen with human
ANCA-associated pauci-immune glomerulonephritis.
Focal pulmonary alveolar capillaritis was identified in
two of the six WT B6 mice that received anti-MPO IgG
(Figure 8f). Three of the WT B6 mice that received anti-
MPO IgG had grossly discernible cutaneous lesions on
the ears. Histologically, all three had focal ulceration and
infarction. Necrotizing arteritis with fibrinoid necrosis
and leukocytoclasia was identified in one specimen (Fig-
ure 8e). The vasculitic lesions caused by anti-MPO IgG
in the WT B6 mice were histologically identical to alveo-
lar capillaritis and necrotizing arteritis in humans with
ANCA-associated vasculitis.
Discussion
This experimental model provides convincing evi-
dence that anti-MPO antibodies cause crescentic
glomerulonephritis and small-vessel vasculitis. All 16
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Table 2
Renal abnormalities in Rag2–/– and WT B6 mice 6 days after they received anti-MPO or anti-BSA IgG
Type of IgG and type of mouse % Crescents % Necrosis BUN (mg/dl) Prot/Hem/Leu
(mean & range) (mean & range) (mean & range) (0–4+)
Anti-MPO IgG in Rag2–/– mice 10.8% (5–15) 13.2% (11–24) 47.4 (34–54) 2.0/2.7/1.8
Anti-BSA IgG in Rag2–/– mice 0% 0% 22.7 (21–25) 1.0/0.5/0.0
No IgG in Rag2–/– mice 0% 0% 21.4 (19–31) 1.0/0.0/0.0
Anti-MPO IgG in WT B6 mice 3.3% (2–6) 4.7% (3–7) 23.3 (21–27) 1.6/2.2/1.2
Anti-BSA IgG in WT B6 mice 0% 0% 25.7 (22–29) 1.0/0.0/0.0
Prot/Hem/Leu, proteinuria/hematuria/leukocyturia.
Figure 6
Systemic vasculitis and granulomatous inflam-
mation in Rag2–/– mice 13 days after receiving
1 × 108 anti-MPO splenocytes. (a) Necrotizing
arteritis in lymph node with transmural fibri-
noid necrosis (arrow) (H&E stain). (b) Necro-
tizing arteritis in spleen with transmural fibri-
noid necrosis (arrow) (Masson trichrome
stain). (c) Intense acute arteritis in lung with
transmural and perivascular infiltration of pre-
dominantly neutrophils (Masson trichrome
stain). (d) Early focal arteritis in lung with neu-
trophils and mononuclear leukocytes invading
the intima (arrow) (Masson trichrome stain).
(e) Pulmonary hemorrhagic capillaritis show-
ing numerous neutrophils marginated within
alveolar septal capillaries (arrow) and red
blood cells in air spaces. (f) Granulomatous
inflammation with multinucleated giant cells
in a lymph node.
Rag2–/– mice that received 5 × 107 or 1 × 108 anti-MPO
splenocytes and all five Rag2–/– mice and all six WT B6
mice that received 50 µg/g anti-MPO IgG developed
glomerular crescents and necrosis. None of 17 Rag2–/–
mice that received anti-BSA splenocytes or anti-BSA
IgG developed glomerular crescents, nor did any of
the mice that received only 1 × 107 anti-MPO spleno-
cytes. None of three WT B6 mice that received anti-
BSA IgG developed crescents.
All Rag2–/– mice that received splenocytes from im-
mune-competent Mpo–/– mice developed low to moder-
ate levels of glomerular immune complex localization.
These immune deposits caused mild to moderate pro-
liferative glomerulonephritis but, in the absence of anti-
MPO, caused little or no renal insufficiency and no
glomerular crescents or necrosis. The basis for the uni-
form production of glomerular immune deposits is not
known but probably relates to the introduction of func-
tioning lymphocytes into mice that previously had no
functioning adaptive immune system. This low to mod-
erate level of glomerular immune complex localization
was the same in intensity and composition in mice irre-
spective of the transfer of anti-MPO, anti-BSA, or con-
trol splenocytes. The basis for this immune complex
glomerulonephritis is unknown. Possibilities include
reactions of the newly synthesized antibodies with cir-
culating exogenous antigens, or production of autoan-
tibodies possibly as a component of a graft-versus-host
reaction. The latter is not likely, since all of the mice had
the same B6 background and thus shared the same
major histocompatibility antigens. Induction of an
autoimmune response remains a possibility; however,
preliminary cell extract immunoprecipitation analysis
of serum from the mice that received splenocytes, per-
formed by Hanno Richards at the University of Florida
(Gainesville, Florida, USA), revealed no autoantibodies,
including no antibodies against DNA, Sm, or ribonu-
cleoproteins (data not shown).
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Figure 7
Glomerular lesions in Rag2–/– mice 6 days
after receiving anti-MPO IgG. (a) Glomeru-
lus with no lesion. (b) Segmental fibrinoid
necrosis (arrow). (c) Segmental fibrinoid
necrosis with an adjacent small cellular
crescent (arrow). (d) Large circumferential
cellular crescent (between arrows) com-
pletely surrounding a glomerulus. (e)
Immunofluorescence microscopy for fibrin
showing prominent staining corresponding
to segmental necrosis and crescent forma-
tion. (f) Immunofluorescence microscopy
for IgG showing a paucity of segmental
staining corresponding to an area of seg-
mental necrosis. Masson trichrome stain-
ing for light microscopy is shown.
Figure 8
Vasculitic lesions in WT B6 mice 6 days after
they received anti-MPO IgG. (a) Glomerulus
with segmental fibrinoid neurosis (periodic
acid Schiff stain). (b) Glomerulus with seg-
mental fibrinoid necrosis and crescent forma-
tion (periodic acid Schiff stain). (c) Glomeru-
lus with segmental fibrinoid necrosis and
crescent formation (H&E stain). (d) Immuno-
fluorescence microscopy for fibrin showing
prominent staining corresponding to segmen-
tal necrosis and crescent formation. (e)
Necrotizing arteritis with leukocytoclasia in
the dermis of the ear (H&E stain). (f) Pul-
monary alveolar capillaritis on the left and
more normal lung on the right.
In striking contrast to Rag2–/– mice that received anti-
BSA or normal control splenocytes, mice that received
anti-MPO splenocytes developed very severe necrotiz-
ing and crescentic glomerulonephritis and small-vessel
vasculitis. This disease induction was dose-dependent,
since all mice that received 5 × 107 or 1 × 108 anti-MPO
splenocytes developed severe crescentic glomeru-
lonephritis but those that received 1 × 107 developed no
crescents at all. This dose effect is in accord with the
serum titers of anti-MPO attained after the different
doses of splenocytes, which were similarly high in mice
that received 5 × 107 or 1 × 108 anti-MPO splenocytes
and substantially lower in those that received 1 × 107
anti-MPO splenocytes (Figure 1).
In addition to necrotizing and crescentic glomeru-
lonephritis, mice that received anti-MPO splenocytes
developed pulmonary hemorrhagic capillaritis and sys-
temic necrotizing arteritis. The lesions were histologi-
cally identical to the pulmonary hemorrhagic capillari-
tis and systemic necrotizing arteritis that occurs in
patients with ANCA-associated small-vessel vasculitis,
such as microscopic polyangiitis and Wegener granulo-
matosis (1, 2). One mouse even had necrotizing granu-
lomatous inflammation in a lymph node that resem-
bled the granulomatous inflammation of Wegener
granulomatosis. Only two or three levels of section of
each organ specimen were evaluated for this study.
Given the focal nature of the vasculitic lesions and gran-
ulomatous inflammation, many more lesions should be
detected by evaluating additional tissue sections.
The transfer of splenocytes introduced both anti-
MPO B lymphocytes and anti-MPO T lymphocytes
into recipient mice. Thus, either MPO-specific T lym-
phocytes or antibodies produced by MPO-specific B
lymphocytes could be mediating the glomerulonephri-
tis and vasculitis in the mice that received splenocytes.
To evaluate the pathogenicity of anti-MPO antibodies
alone (i.e., MPO-ANCAs), purified anti-MPO IgG or
anti-BSA IgG was injected into Rag2–/– mice and WT B6
mice. All five Rag2–/– mice and all six WT B6 mice that
received anti-MPO IgG developed focal glomerular
necrosis and crescent formation, whereas none of the
six mice that received anti-BSA IgG did. This demon-
strates that anti-MPO IgG causes glomerular necrosis
and crescents in the absence of antigen-specific T and
B lymphocytes in Rag2–/– mice and in the presence of a
competent immune system in WT B6 mice. The
glomerular lesions that were caused in mice by anti-
MPO IgG were identical by light microscopy and
immunofluorescence microscopy to the glomerular
lesions of human ANCA-associated pauci-immune
glomerulonephritis and small-vessel vasculitis (1, 2).
Both mouse and human glomerular lesions have fibri-
noid necrosis, crescent formation, and an absence or
paucity of staining for Ig’s by immunofluorescence
microscopy. The WT B6 mice also developed vasculitic
lesions identical to human ANCA-associated disease in
other organs, including pulmonary alveolar capillaritis
and cutaneous necrotizing arteritis.
The so-called pauci-immune characteristic of ANCA-
associated glomerulonephritis is pathologically very
distinct from the substantial vessel wall localization of
Ig’s in immune complex–mediated glomerulonephritis
and glomerulonephritis induced by anti–glomerular
basement membrane (anti-GBM) antibody. This sug-
gests that the pathogenesis of pauci-immune ANCA-
associated glomerulonephritis is distinct from that for
immune complex glomerulonephritis or anti-GBM
glomerulonephritis. This distinct mechanism appears
to involve ANCA-induced activation of neutrophils
and monocytes. ANCA IgG can activate neutrophils
and monocytes in vitro (5, 6). For example, ANCA IgG
stimulates cytokine-primed neutrophils to release inju-
rious oxygen metabolites and proteinases (11–13). Acti-
vation of neutrophils by ANCA IgG also induces the
release of numerous proinflammatory cytokines, such
as IL-1, IL-8, and leukotrienes (14–16). Monocytes also
have ANCA antigens, including MPO and PR3, and can
be induced to undergo a respiratory burst and release
of proteinases and cytokines after stimulation by
ANCA IgG (17–19). Neutrophils that have been acti-
vated by ANCA IgG are capable of adhering to and
killing endothelial cells in vitro (20, 21).
In vitro and in vivo experiments indicate that the acti-
vation of neutrophils and monocytes by ANCA and the
induction of tissue injury by ANCA are facilitated by
minor inflammatory stimuli that prime leukocytes to
interact with ANCA (5–7). This priming causes
increased expression of ANCA antigens, such as MPO,
at the surface of neutrophils and monocytes where the
antigens can interact with ANCA and cause leukocyte
activation. The greater severity of the glomerulonephri-
tis induced by anti-MPO splenocytes compared with
that induced by anti-MPO IgG might be due to the syn-
ergistic presence of the glomerular immune complexes
in the former acting as a priming factor for leukocytes.
An alternative explanation is that anti-MPO T lympho-
cytes that are transferred into the recipients with the
splenocytes might have an additive effect on the severi-
ty of the vascular inflammatory injury.
The in vitro data that document the ability of ANCA
IgG to activate neutrophils and monocytes, combined
with the current mouse model of ANCA-induced
glomerulonephritis and vasculitis, strongly support a
primary pathogenic role for ANCA in ANCA-associated
glomerulonephritis and vasculitis. Using the Bradford
Hill criteria for causation (22), the clinical and experi-
mental evidence that is now available strongly indicates
that ANCAs cause ANCA-associated glomerulonephri-
tis and small-vessel vasculitis. The Bradford Hill criteria
for concluding that an association is indicative of cau-
sation are: 1, strength; 2, specificity; 3, consistency; 4,
temporality; 5, biological gradient; 6, experimental evi-
dence; 7, coherence; and 8, analogy.
Criteria 1 and 2 are fulfilled by the very strong and
specific clinical association between ANCAs and pauci-
immune crescentic glomerulonephritis and small-ves-
sel vasculitis (1, 2). Approximately 80–90% of active
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untreated patients with pauci-immune necrotizing and
crescentic glomerulonephritis and vasculitis have cir-
culating MPO-ANCA or PR3-ANCA. Less than 10% of
patients with other types of glomerulonephritis and
vasculitis have ANCA, and less than 1% of the general
population has ANCA.
Criterion 3 is fulfilled by the virtually complete con-
sistency among research groups throughout the
world in demonstrating the association between
ANCAs and pauci-immune glomerulonephritis and
small-vessel vasculitis.
Criteria 4, 5, and 6 have been difficult to document
clinically, but the experimental data in this article show
that crescentic glomerulonephritis and small-vessel
vasculitis develop within a few days after introduction
of ANCA into experimental animals (temporality), and
that the occurrence and magnitude of this effect is
dose-dependent (gradient).
Criterion 7 is fulfilled by the coherence of the in vitro
observations that ANCA IgG causes activation of neu-
trophils and monocytes with the in vivo pathologic
observations that the acute phase of injury is charac-
terized by necrotizing acute inflammation that is medi-
ated by activated neutrophils and monocytes.
Criterion 8 is fulfilled by the analogy between MPO
and PR3, which are the two major antigenic targets of
ANCAs. Although they are very different molecules
with very different biological function, MPO and PR3
have the same locations in the cytoplasm of neu-
trophils and monocytes, are similarly displayed and
released during varying phases of activation, and are
both targeted by ANCAs. These analogies between
MPO and PR3 support the pathogenic potential not
only of MPO-ANCA but also of PR3-ANCA.
Thus, based on the experimental model described
here, we conclude that the association in patients
between ANCAs and pauci-immune glomerulone-
phritis and vasculitis is most likely due to causation.
Therefore, we propose that the often-used terms
“ANCA-associated glomerulonephritis” and “ANCA-
associated vasculitis” should be changed to “ANCA
glomerulonephritis” and “ANCA vasculitis.” The
results of these studies suggest that therapeutic
strategies that selectively eliminate or neutralize
ANCAs could be effective in treating ANCA glomeru-
lonephritis and vasculitis.
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